Effect of Metoclopramide on Small Bowel Motility
Mechanism of Action and Effects
- Metoclopramide acts as a D2 dopamine receptor antagonist that stimulates gastric emptying and small intestinal transit, according to the European Society of Gastrointestinal Motility, 1, 2
Clinical Applications and Limitations
- The European Medicines Agency recommends against long-term use of metoclopramide due to risk of extrapyramidal side effects and potentially irreversible tardive dyskinesia, especially in elderly patients, with a strength of evidence considered high 1, 2, 3
- Metoclopramide should be used with caution after bowel anastomosis as prokinetic drugs are generally not recommended in this setting, as suggested by the European Society of Gastrointestinal Motility 2
Alternative Prokinetic Agents
- Erythromycin, a motilin agonist, may be more effective for small bowel dysmotility, particularly in cases with absent or impaired antroduodenal migrating complexes, according to the American Gastroenterological Association 3, 4
- Azithromycin has been suggested as potentially more effective than erythromycin for small bowel dysmotility, with moderate strength of evidence 3, 4
- Prucalopride, a selective 5-HT4 receptor agonist, has been used for constipation and appears to have fewer cardiac risks than older agents like cisapride, as recommended by the American College of Gastroenterology 3, 4
- Octreotide, a somatostatin analogue, may be beneficial in cases of small intestinal dysmotility, especially when other treatments have failed, with low strength of evidence 3, 4